Azasugar Triphosphate Synthesis via Protected Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in isolating and purifying biologically active 5′-triphosphate forms of nucleoside analogues, such as galidesivir, in sufficient quantities for use as analytical standards, due to the complexity of direct chemical synthesis arising from multiple functional groups with varying reactivities.
Innovation Solution
A method is developed for the efficient synthesis of the 5′-triphosphate form of azasugar nucleoside analogues, including galidesivir, through the selective formation of protected intermediates, simplifying the process and enabling scalable production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct chemical synthesis is attempted on 5′-triphosphate forms of nucleoside analogues, then the biologically active form can be produced, but the process becomes complex and difficult to purify due to multiple functional groups with varying reactivities
Solution Approach 1:
The synthesis is divided into distinct stages: first forming protected intermediates with specific protecting groups on hydroxyl groups, then performing phosphorylation on the protected compound, and finally removing protecting groups to yield the pure triphosphate form. This segmentation allows each step to be optimized independently, reducing overall complexity.
Solution Approach 2:
Protecting groups are introduced beforehand to mask reactive hydroxyl groups before phosphorylation. This preliminary action prevents unwanted side reactions and simplifies purification by ensuring that only the desired 5′-triphosphate product is formed, with other hydroxyl groups remaining protected or unreactive.
2Ease of manufacture
If protected intermediates are formed selectively, then the synthesis process is simplified and becomes scalable, but additional steps are required compared to direct synthesis
Solution Approach 1:
The method employs specific protecting groups (such as acetyl, benzoyl, or silyl groups) that can be selectively introduced and removed under mild conditions. The choice of protecting group parameters (stability, ease of introduction, ease of removal) is optimized to balance the number of steps with overall efficiency, making the process both simple and scalable.
Solution Approach 2:
Protected intermediates serve as stable mediators that facilitate the phosphorylation step. These intermediates are easier to handle and purify than the final triphosphate product, and their use enables scalable production while the additional steps involve well-established, efficient reactions that minimize time loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of biologically active 5′-triphosphate forms of azasugar nucleosides, facilitating their use as analytical standards and addressing the difficulties in isolation and purification.
Implementation Method 1
combining compound 1b or a salt thereof and a phosphorylation reagent, thereby producing compound 1b1 or a salt thereof
Data Source
AI summary
Provided are methods of making the active 5′-triphosphate form of galidesivir (compound 1) and the active 5′-triphosphate form of azasugar nucleoside analogues (compound 2):a potent anti-viral compound useful for broad spectrum treatment, suppression, and prevention of viral infections. The syntheses of compound 1 and compound 2 can be achieved via selective formation of protected intermediate 1b and protected intermediate 2b, respectively: